Phase 1 to Phase 2:  What Should Be Done during the Early Stages of Drug Development? Submitting the appropriate information for an IND application, especially the solid state aspects of the drug substance (DS), can accelerate new drugs into clinical trials.  Having the appropriate information from a physicochemical perspective will […]

Delay Method Development at Your Own Peril! Small and virtual pharma companies mindful of constrained budgets often defer analytical method development until later stages. But delaying analytical process development from pre-clinical to IND or NDA stages bears its own costs…and they can be exorbitant. Need to Develop Analytical Methods? Start […]

Over the last twenty years or so, the paradigm behind setting specifications has undergone something of a transformation. Much can be attributed to the adoption of risk-based methodologies, such as Quality by Design (QbD), advancements in technology, and harmonization of world regulatory expectations. The Art of Medicinal Science Specification setting […]

Successful pharmaceutical project onboarding – whether at a CRO, CMO or CDMO – hinges on three key factors: Flexibility Communication Relationships. All of these factors depend heavily on the project team. Select the Right Project Manager One of the most important elements of successful drug substance project onboarding is project […]

The objective of drug development is to successfully get a lead compound into clinical trials and ultimately to the patient population – as quickly as possible. Yet, just as important as speed is safety. In fact, if the applied analytical methods are not measuring the right parameters, speed-to-market becomes a […]